Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc

706.16
USD
+7.82
(+1.12%)
19.02EPS
35.53P/E
250.12BMarket Cap
Feb 04Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
36.33
42.41
42.55
46.29
52.96
60.59
63.86
81.36
99.52
114.58
111.03
112.25
118.19
127.2
Basic EPS, GAAP
3.53
4.76
4.95
5.12
5.63
7.31
9.24
16.1
19.61
17.73
15.53
16.58
17.78
19
Free Cash Flow per Basic Share
4.8
5.5
6.32
7.13
8.85
9.42
10.12
17.21
17.23
17.63
17.95
19.02
16.69
20.41
Dividend per Share
0.6
0.59
0.6
0.6
0.6
0.66
0.74
0.85
1
1.16
1.35
1.53
1.69
1.81
Book Value per Share
46.57
51.31
53.42
54.75
63.32
68.6
74.42
86.99
103.42
112.62
120.87
130.22
141.96
147.8
Tangible Book Value per Share
-7.51
-30.98
-25.61
-34.97
-41.27
-31.68
-25.21
-10.64
-53.86
-37.54
-36.09
-30.99
-31.35
-47.44
Basic Weighted Avg Shares
360
398
399
395
395
402
400
396
394
392
386
382
377
372
Sales/Revenue/Turnover
13,090
16,890
16,965
18,274
20,918
24,358
25,542
32,218
39,211
44,915
42,857
42,879
44,557
47,351
Operating Margin (%)
12.89
11.28
14.45
14.49
14.61
15.74
16.37
24.5
26.08
18.94
17.08
18
18.2
18.72
Depreciation Expense
1,000
1,685
1,688
1,758
2,033
2,267
2,277
2,325
2,592
3,381
3,406
3,108
2,780
3,106
Net Income, GAAP
1,273
1,894
1,975
2,022
2,225
2,938
3,696
6,375
7,725
6,950
5,995
6,335
6,704
7,072
Effective Tax Rate (%)
3.06
9.18
- -
- -
8.28
9.93
9.18
11.76
12.54
8.97
4.51
9.34
7.48
9.39
Profit Margin (%)
9.73
11.22
11.64
11.06
10.64
12.06
14.47
19.79
19.7
15.47
13.99
14.77
15.05
14.94
Working Capital
6,755
1,190
1,595
2,155
2,373
4,478
5,696
11,653
6,677
8,219
10,577
8,805
13,518
11,445
LT Debt
9,500
12,352
11,420
15,372
18,873
17,719
17,076
19,107
32,333
28,909
31,308
29,061
35,852
39,108
Total Equity
16,856
20,548
21,350
21,540
25,413
27,586
29,675
34,517
40,977
44,148
46,842
49,672
53,536
54,896
Return on Invested Capital (%)
6.26
7.27
- -
- -
6.42
7.35
8.9
13.3
13.31
9.91
8.19
8.2
8.26
8.39
Return on Capital (%)
6.12
7.46
- -
- -
6.54
7.61
9.17
13.24
12.4
9.84
9.16
9.33
9.2
9.22
Return on Common Equity (%)
7.88
10.13
9.43
9.43
9.48
11.09
12.91
19.87
20.52
16.4
13.22
13.15
13.02
13.37

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3,090
3,368
2,262
LT Borrowings
40,071
39,181
39,108
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
372
370
371
Market Capitalization
182,663
185,376
250,117

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
22,316
23,365
25,615
Cash, Cash Equivalents & STI
3,256
4,064
6,061
Accounts Receivable, Net
9,204
9,451
9,625
Inventories
5,496
5,627
5,643
Total Current Liabilities
14,621
15,069
14,170
Payables & Accruals
8,603
8,785
8,967
ST Debt
3,090
3,368
2,262
Deferred Revenue
2,928
2,918
2,941

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.77%
9.28%
7.78%
Free Cash Flow
11.27%
-1.37%
-13.4%
Net Income, GAAP
15.16%
1.78%
5.82%
Sales/Revenue/Turnover
10.53%
7.13%
3.91%
Total Cash Common Dividend
10.36%
13.58%
9.09%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,345
10,541
10,598
11,395
42,879
2025
10,364
10,854
11,122
12,215
44,557
2026
11,005
11,994
12,137
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.48
4.05
4.27
4.79
16.58
2025
3.99
4.28
4.28
5.22
17.78
2026
4.44
4.68
4.65
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.39
0.39
0.39
1.53
2025
0.39
0.43
0.43
0.43
1.69
2026
0.44
0.47
0.47
- -
- -

Company Description

CEO
Marc N. Casper
Full Time Employees
125,000
Sector
Health technology
Industry
Medical specialties
Address
168 Third Avenue Waltham MA United States 02451
IPO Date
Aug 27, 1980
Business
Thermo Fisher Scientific Inc. (NYSE: TMO) provides analytical instruments, equipment, software, services, consumables, and reagents for research, analysis, discovery, and diagnostics worldwide. The company offers products including mass spectrometry systems, chromatography instruments, genetic analysis tools, bioprocessing equipment, clinical diagnostics assays, laboratory automation solutions, and electron microscopy technologies; its key brands encompass Thermo Scientific, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon. Headquartered in Waltham, Massachusetts, Thermo Fisher was originally founded in 1902 through the merger of Fisher Scientific and Thermo Electron in 2006, and operates in over 70 countries serving pharmaceutical, biotechnology, academic, government, and healthcare customers across life sciences, analytical technologies, specialty diagnostics, and laboratory products segments. Recently, the company expanded its capabilities through the acquisition of Olink Holding AB in 2024 to bolster proteomics offerings, launched the new Orbitrap Astral mass spectrometer in late 2024 for high-throughput proteomics, and formed strategic partnerships including a multi-year collaboration with AstraZeneca to advance biomarker discovery; in 2025, Thermo Fisher announced expansions in gene editing technologies and sustainable manufacturing initiatives amid ongoing supply chain optimizations.

Company News

  • Jim Cramer Calls Big Tech ‘Millstones' and Names the ‘New Techs' Taking Over

  • 15,095 Thermo Fisher Scientific Inc. $TMO Shares Sold by Bank Julius Baer & Co. Ltd Zurich

  • Thermo Fisher Scientific Inc. $TMO Shares Newly Bought by Associated Banc Corp

  • Thermo Fisher Scientific Inc. $TMO Stock: BOCHK Asset Management Ltd Lowers Position

  • Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet

  • Parnassus Value Equity Fund Q3 2026 Portfolio Review

  • Is TMO Overvalued? DCF Says Worth $352

  • Baron Health Care Fund Q3 2026 Top Contributors And Detractors

  • Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More

  • Thermo Fisher: You Don't Need A Microscope To See The Growth Anymore

  • Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors

  • Thermo Fisher Stocks Rise 1.0% as Revenue Growth Beats Estimates

  • Nasdaq Gains 1%; Thermo Fisher Scientific Posts Upbeat Earnings

  • Thermo Fisher Scientific Inc. (TMO) Q3 2026 Earnings Call Transcript

  • TMO Q3 Earnings & Revenues Beat Estimates, Stock Down in Pre-Market

  • Compared to Estimates, Thermo Fisher (TMO) Q3 Earnings: A Look at Key Metrics

  • Thermo Fisher Q3: The Recovery Is Real, And I'm Still Buying

  • Thermo Fisher Scientific Q3 Earnings Call Highlights

  • Thermo Fisher posts higher third-quarter revenue and earnings as margins improve

  • Thermo Fisher Scientific (TMO) Tops Q3 Earnings and Revenue Estimates